차세대 당뇨병 치료 및 약물전달 시장 : 제품 유형, 인구통계, 적응증, 최종 사용자, 지역별(2026-2034년)

The global next generation diabetes therapy and drug delivery market size reached USD 12.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 39.3 Billion by 2034, exhibiting a growth rate (CAGR) of 12.98% during 2026-2034. The rising prevalence of diabetes, particularly type-2 diabetes, continual technological advancements, and the growing geriatric population represent some of the key factors driving the market.

Next generation diabetes therapy and drug delivery procedure focuses on the introduction of insulin into the patient's body in a minimally invasive manner to reduce the risk of skin irritation from frequent needle usage. This patient-friendly approach aims to effectively manage the disease while reducing healthcare costs by utilizing innovative technologies including wearable sensors, micro-needles, and inhalable insulin. Advanced therapies, such as continuous glucose monitoring systems (CGMS), artificial pancreas, and insulin patches, are also employed to improve blood sugar level management that minimize the risks of diabetic-related complications. In addition, the procedure facilitates easy calculation of the dose volume, checking the blood glucose levels in real-time, and delivers insulin into the body painlessly, which, in turn, helps to maintain the dosage time. Some of the advantages of this therapy and drug delivery practice includes improved patient outcomes, enhanced treatment efficiency, and minimized burden of diabetes management for patients, leading to more targeted treatment plans.

NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TRENDS:

The global market is primarily driven by the rising prevalence of diabetes, particularly type-2 diabetes, among the masses. This can be attributed to the increasing consumption of unhealthy diets, sedentary lifestyles and reduced physical activity. In line with this, the augmenting demand for personalized and patient-centric care according to individual needs, lifestyle, and treatment goals is resulting in a higher product uptake. Moreover, continual technological advancements, such as the development of smart insulin pens, closed-loop systems, and implantable devices with fewer side effects, is providing an impetus to the market. In addition to this, the increasing emphasis on minimally invasive and pain-free treatment options among individuals is also acting as a significant growth-inducing factor for the market. The market is further driven by the increasing healthcare expenditure, along with an enhanced focus on value-based medical care solutions. However, the growing cost restrains, lack of awareness and less variability in products in the developing regions are acting as major growth-restraining factors for the market. Conversely, the implementation of favorable government initiatives and reimbursement policies regarding preventive healthcare and early intervention is creating a positive outlook for the market. Apart from this, the growing geriatric population that is more susceptible to developing chronic diseases is impacting the market favorably. Some of the other factors contributing to the market include rapid urbanization, increasing awareness regarding the associated complications of traditional diabetes treatment, rising adoption of telehealth and digital health solutions, inflating disposable income levels and extensive research and development (R&D) activities conducted by key players.

KEY MARKET SEGMENTATION:

Product Type Insights:

• Inhalable Insulin
• Oral Insulin
• Insulin Patches
• CGM Systems
• Artificial Pancreas

Demographic Insights:

• Adult Population (>14 Years)
• Child Population (14 Years)

Indication Insights:

• Type 1 diabetes
• Type 2 diabetes

End User Insights:

• Diagnostic/Clinics
• Intensive Care Units (ICUs)
• Home Healthcare

Regional Insights:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for next generation diabetes therapy and drug delivery. Some of the factors driving the North America next generation diabetes therapy and drug delivery market included the aging population, continual technological advancements, high healthcare expenditure, etc.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global next generation diabetes therapy and drug delivery market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Dexcom Inc., Eli Lilly and Company, Enteris BioPharma Inc. (Swk Holdings Corporation), GlySens Incorporated, MannKind Corporation, Medtronic plc, Sanofi, Senseonics, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global next generation diabetes therapy and drug delivery market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global next generation diabetes therapy and drug delivery market?
• What is the impact of each driver, restraint, and opportunity on the global next generation diabetes therapy and drug delivery market?
• What are the key regional markets?
• Which countries represent the most attractive global next generation diabetes therapy and drug delivery market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the global next generation diabetes therapy and drug delivery market?
• What is the breakup of the market based on the demographic?
• Which is the most attractive demographic in the global next generation diabetes therapy and drug delivery market?
• What is the breakup of the market based on the indication?
• Which is the most attractive indication in the global next generation diabetes therapy and drug delivery market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the global next generation diabetes therapy and drug delivery market?
• What is the competitive structure of the global next generation diabetes therapy and drug delivery market?
• Who are the key players/companies in the global next generation diabetes therapy and drug delivery market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Next Generation Diabetes Therapy and Drug Delivery Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Inhalable Insulin
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Oral Insulin
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Insulin Patches
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 CGM Systems
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Artificial Pancreas
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Demographic

• 7.1 Adult Population (>14 Years)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Child Population (14 Years)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Indication

• 8.1 Type 1 Diabetes
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Type 2 Diabetes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by End User

• 9.1 Diagnostic/Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Intensive Care Units (ICUs)
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Home Healthcare
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

• 11.1 Overview
• 11.2 Drivers
• 11.3 Restraints
• 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Dexcom Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Eli Lilly and Company
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Enteris BioPharma Inc. (Swk Holdings Corporation)
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 GlySens Incorporated
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 MannKind Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Medtronic plc
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Sanofi
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Senseonics
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials